Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24538153 | 0.78 | MEN1 (0.38) | GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL6158270 | 0.77 | ENPP2 (0.36) | GSK3AGSK3BMEN1KMT2APIK3CD | |
| SCHEMBL18937480 | 0.74 | PIK3CD (0.33) | GSK3AGSK3BMEN1KMT2APIK3CD | |
| SCHEMBL22921234 | 0.74 | ENPP2 (0.35) | GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL19059657 | 0.74 | MEN1 (0.35) | GSK3AGSK3BMEN1KMT2APOLB | |
| SCHEMBL23666002 | 0.74 | ENPP2 (0.33) | GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL11876303 | 0.72 | GSK3A (0.38) | GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL8675744 | 0.72 | OPRM1 (0.40) | MEN1KMT2APOLB | |
| SCHEMBL3626726 | 0.72 | — | — | |
| SCHEMBL12552509 | 0.72 | GSK3A (0.34) | GSK3AGSK3BMEN1KMT2APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20220194948-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | ILDONG PHARACEUTICAL CO., LTD. (KR) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | GSK3A 1675/4885GSK3B 1484/4885MEN1 3616/4885 |
| US-20220194948-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | AR, PDE5A, PDE1A | GSK3A 467/4885GSK3B 398/4885MEN1 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.